[M03AB01, succinylcholine, The risk or severity of bradycardia can be increased when Succinylcholine is combined with Butorphanol.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Butorphanol.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Butorphanol is combined with Sulthiame.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Temazepam.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Apomorphine.]
[L04AX02, thalidomide, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The therapeutic efficacy of Theobromine can be decreased when used in combination with Butorphanol.]
[R06AD03, thiethylperazine, The risk or severity of hypotension and CNS depression can be increased when Thiethylperazine is combined with Butorphanol.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Butorphanol.]
[N05AB08, thioproperazine, The risk or severity of hypotension and CNS depression can be increased when Thioproperazine is combined with Butorphanol.]
[N05AC02, thioridazine, The risk or severity of hypotension and CNS depression can be increased when Thioridazine is combined with Butorphanol.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Butorphanol is combined with Thiothixene.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tiapride.]
[N02AX01, tilidine, The therapeutic efficacy of Tilidine can be decreased when used in combination with Butorphanol.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Tramadol.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Butorphanol.]
[C03DB02, triamterene, The therapeutic efficacy of Triamterene can be decreased when used in combination with Butorphanol.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Triazolam.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Butorphanol.]
[A03AB12, mepenzolate, The risk or severity of adverse effects can be increased when Mepenzolate is combined with Butorphanol.]
[N05AB06, trifluoperazine, The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Butorphanol.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Trifluperidol.]
[N05AA05, triflupromazine, The risk or severity of adverse effects can be increased when Triflupromazine is combined with Butorphanol.]
[N04AA01, trihexyphenidyl, The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Butorphanol.]
[A03AA05, trimebutine, The risk or severity of adverse effects can be increased when Trimebutine is combined with Butorphanol.]
[R06AD01, trimeprazine, The risk or severity of hypotension and CNS depression can be increased when Alimemazine is combined with Butorphanol.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Butorphanol.]
[C02BA01, trimethaphan, The risk or severity of adverse effects can be increased when Trimethaphan is combined with Butorphanol.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Butorphanol.]
[A03BB01, butylscopolamine, The risk or severity of adverse effects can be increased when Butylscopolamine is combined with Butorphanol.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Butorphanol.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Butorphanol.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ezogabine.]
[B01AC24, ticagrelor, Butorphanol can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Viloxazine.]
[C03BA10, xipamide, The therapeutic efficacy of Xipamide can be decreased when used in combination with Butorphanol.]
[N05AF05, zuclopenthixol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Levetiracetam.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ziprasidone.]
[G03AC10, drospirenone, The therapeutic efficacy of Drospirenone can be decreased when used in combination with Butorphanol.]
[G04BD07, tolterodine, The risk or severity of adverse effects can be increased when Tolterodine is combined with Butorphanol.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Atracurium is combined with Butorphanol.]
[S01FA01, atropine, The risk or severity of adverse effects can be increased when Atropine is combined with Butorphanol.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Lorcaserin.]
[A06AX04, linaclotide, The therapeutic efficacy of Linaclotide can be decreased when used in combination with Butorphanol.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Butorphanol.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Butorphanol is combined with Rasagiline.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Butorphanol is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Butorphanol is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Butorphanol.]
[R06AC06, thonzylamine, The risk or severity of adverse effects can be increased when Thonzylamine is combined with Butorphanol.]
[G04BD10, darifenacin, The risk or severity of adverse effects can be increased when Darifenacin is combined with Butorphanol.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Butorphanol is combined with Diethyl ether.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Butorphanol.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pomalidomide.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Benperidol.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be decreased when used in combination with Butorphanol.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Benzocaine.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Butorphanol is combined with Naratriptan.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Benzatropine is combined with Butorphanol.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Levomilnacipran.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Vortioxetine.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Eslicarbazepine.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be decreased when used in combination with Butorphanol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tasimelteon.]
[A03BA03, hyoscyamine, The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Butorphanol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Alfaxalone.]
[D11AA01, glycopyrronium, The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Butorphanol.]
[N05CM19, suvorexant, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[N05AA04, acepromazine, The risk or severity of hypotension and CNS depression can be increased when Acepromazine is combined with Butorphanol.]
[A06AB04, phenolphthalein, The therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Butorphanol.]
[A06AH03, naloxegol, Butorphanol may increase the opioid antagonism activities of Naloxegol.]
[N04AA02, biperiden, The risk or severity of adverse effects can be increased when Biperiden is combined with Butorphanol.]
[A06AG02, bisacodyl, The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Butorphanol.]
[N06AX11, mirtazapine, Butorphanol may increase the serotonergic activities of Mirtazapine.]
[A03AA09, difemerine, The risk or severity of adverse effects can be increased when Difemerine is combined with Butorphanol.]
[A07DA06, eluxadoline, The risk or severity of constipation can be increased when Butorphanol is combined with Eluxadoline.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Butorphanol is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Flibanserin.]
[A06AD03, magnesium peroxide, The therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Butorphanol.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of hypotension and CNS depression can be increased when Acetophenazine is combined with Butorphanol.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Butorphanol.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Butorphanol.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Amineptine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Aniracetam.]
[C03CA02, bumetanide, The therapeutic efficacy of Bumetanide can be decreased when used in combination with Butorphanol.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Butorphanol.]
[N07BC01, buprenorphine, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Butorphanol.]
[S01GX07, azelastine, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[A06AX07, plecanatide, The therapeutic efficacy of Plecanatide can be decreased when used in combination with Butorphanol.]
[A06AH05, naldemedine, The therapeutic efficacy of Butorphanol can be decreased when used in combination with Naldemedine.]
[N02BF02, pregabalin, The therapeutic efficacy of Butorphanol can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Beclamide.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Butorphanol.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Safinamide.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Butorphanol is combined with Efavirenz.]
[N04AA11, bornaprine, The risk or severity of adverse effects can be increased when Bornaprine is combined with Butorphanol.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Brotizolam.]
[C03DA03, canrenone, The therapeutic efficacy of Canrenone can be decreased when used in combination with Butorphanol.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Butorphanol.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Butorphanol is combined with Butriptyline.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be decreased when used in combination with Butorphanol.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Butorphanol is combined with Vinylbital.]
[N03AF01, carbamazepine, The risk or severity of adverse effects can be increased when Carbamazepine is combined with Butorphanol.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Butorphanol.]
[A03AA03, camylofine, The risk or severity of adverse effects can be increased when Camylofin is combined with Butorphanol.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Carbinoxamine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Butorphanol.]
[N03AX17, stiripentol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Butorphanol.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Butorphanol is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, The risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Butorphanol.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Butorphanol.]
[R03BB08, revefenacin, The risk or severity of adverse effects can be increased when Revefenacin is combined with Butorphanol.]
[A06AX05, prucalopride, The therapeutic efficacy of Prucalopride can be decreased when used in combination with Butorphanol.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Butorphanol is combined with Cinitapride.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Esketamine.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Clobazam.]
[A06AB05, castor oil, The therapeutic efficacy of Castor oil can be decreased when used in combination with Butorphanol.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Cloxazolam.]
[N05AA06, cyamemazine, The risk or severity of hypotension and CNS depression can be increased when Cyamemazine is combined with Butorphanol.]
[C03BX03, cicletanine, The therapeutic efficacy of Cicletanine can be decreased when used in combination with Butorphanol.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Butorphanol.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Cyclothiazide can be decreased when used in combination with Butorphanol.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Yohimbine.]
[A06AB03, danthron, The therapeutic efficacy of Dantron can be decreased when used in combination with Butorphanol.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Butorphanol.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Butorphanol.]
[N02AX03, dezocine, The therapeutic efficacy of Dezocine can be decreased when used in combination with Butorphanol.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Butorphanol is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Lumateperone.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Butorphanol is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Dichloralphenazone.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Butorphanol.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Butorphanol.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Chlordiazepoxide.]
[A03AA08, dihexyverine, The risk or severity of adverse effects can be increased when Dihexyverine is combined with Butorphanol.]
[G04BD09, trospium, The risk or severity of adverse effects can be increased when Trospium is combined with Butorphanol.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Butorphanol is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Dyclonine.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Butorphanol is combined with Remimazolam.]
[N07XX04, sodium oxybate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Sodium oxybate.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Butorphanol is combined with Oliceridine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Butorphanol.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Butorphanol.]
[N05AF03, chlorprothixene, The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Butorphanol.]
[C03BA04, chlorthalidone, The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Butorphanol.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Butorphanol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl loflazepate.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Felbamate.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Butorphanol is combined with Trichloroethylene.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Gabapentin.]
[N06AB04, citalopram, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Citalopram.]
[C03DA05, finerenone, The therapeutic efficacy of Finerenone can be decreased when used in combination with Butorphanol.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Butorphanol.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Butorphanol is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Butorphanol.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Levobupivacaine.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Clomipramine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Butorphanol.]
[C03BA03, clopamide, The therapeutic efficacy of Clopamide can be decreased when used in combination with Butorphanol.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Butorphanol is combined with Granisetron.]
[N05AH02, clozapine, The risk or severity of adverse effects can be increased when Clozapine is combined with Butorphanol.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Halazepam.]
[S02DA02, cocaine, The risk or severity of adverse effects can be increased when Cocaine is combined with Butorphanol.]
[C02KB01, metyrosine, Butorphanol may increase the sedative activities of Metyrosine.]
[R05DA04, codeine, The therapeutic efficacy of Codeine can be decreased when used in combination with Butorphanol.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Butorphanol.]
[A03AB10, hexocyclium, The risk or severity of adverse effects can be increased when Hexocyclium is combined with Butorphanol.]
[A03BB06, homatropine methylbromide, The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Butorphanol.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Butorphanol is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ifenprodil.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Butorphanol.]
[H01AX01, pegvisomant, The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Butorphanol.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Butorphanol is combined with Almotriptan.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ketazolam.]
[A06AD12, lactitol, The therapeutic efficacy of Lactitol can be decreased when used in combination with Butorphanol.]
[N03AX09, lamotrigine, The risk or severity of adverse effects can be increased when Lamotrigine is combined with Butorphanol.]
[N07BC04, lofexidine, The therapeutic efficacy of Butorphanol can be increased when used in combination with Lofexidine.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Lormetazepam.]
[A06AD01, magnesium carbonate, The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Butorphanol.]
[A03AA04, mebeverine, The risk or severity of adverse effects can be increased when Mebeverine is combined with Butorphanol.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Medifoxamine.]
[N04AA03, methixene, The risk or severity of adverse effects can be increased when Metixene is combined with Butorphanol.]
[R03CB02, methoxyphenamine, Methoxyphenamine may increase the analgesic activities of Butorphanol.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclobarbital.]
[C03DA04, eplerenone, The therapeutic efficacy of Eplerenone can be decreased when used in combination with Butorphanol.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Butorphanol is combined with Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Butorphanol.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Minaprine.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Moclobemide.]
[R06AX02, cyproheptadine, The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Butorphanol.]
[C03XA02, conivaptan, The therapeutic efficacy of Conivaptan can be decreased when used in combination with Butorphanol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Butorphanol is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[N07BB05, nalmefene, The therapeutic efficacy of Butorphanol can be decreased when used in combination with Nalmefene.]
[B05XA15, potassium lactate, The therapeutic efficacy of Potassium lactate can be decreased when used in combination with Butorphanol.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Nordazepam.]
[N06AX06, nefazodone, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Niaprazine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tiagabine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Butorphanol.]
[R05DA06, normethadone, The therapeutic efficacy of Normethadone can be decreased when used in combination with Butorphanol.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of adverse effects can be increased when Solifenacin is combined with Butorphanol.]
[N06AA01, desipramine, The risk or severity of adverse effects can be increased when Desipramine is combined with Butorphanol.]
[H01BA02, desmopressin, The risk or severity of hyponatremia can be increased when Butorphanol is combined with Desmopressin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Oxcarbazepine.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Oxiracetam.]
[N04AA08, dexetimide, The risk or severity of adverse effects can be increased when Dexetimide is combined with Butorphanol.]
[G04BD04, oxybutynin, The risk or severity of adverse effects can be increased when Oxybutynin is combined with Butorphanol.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Butorphanol.]
[N06BA02, dextroamphetamine, Amphetamine may increase the analgesic activities of Butorphanol.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Butorphanol.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Butorphanol is combined with Paramethadione.]
[N02AC01, dextromoramide, The therapeutic efficacy of Dextromoramide can be decreased when used in combination with Butorphanol.]
[N06AB05, paroxetine, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Paroxetine.]
[B01AC04, clopidogrel, Butorphanol can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N07BC06, heroin, The therapeutic efficacy of Diamorphine can be decreased when used in combination with Butorphanol.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Phenacemide.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Butorphanol.]
[S01EC02, dichlorphenamide, The therapeutic efficacy of Diclofenamide can be decreased when used in combination with Butorphanol.]
[A03AA07, dicyclomine, The risk or severity of adverse effects can be increased when Dicyclomine is combined with Butorphanol.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pipamperone.]
[A03AB14, pipenzolate, The risk or severity of adverse effects can be increased when Pipenzolate is combined with Butorphanol.]
[C03CA03, piretanide, The therapeutic efficacy of Piretanide can be decreased when used in combination with Butorphanol.]
[A08AA03, diethylpropion, Diethylpropion may increase the analgesic activities of Butorphanol.]
[A03AB11, poldine, The risk or severity of adverse effects can be increased when Poldine is combined with Butorphanol.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Butorphanol.]
[N02AA03, hydromorphone, The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Butorphanol.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pramocaine.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Dimenhydrinate.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pridinol.]
[R06AB03, dimethindene, The risk or severity of adverse effects can be increased when Dimetindene is combined with Butorphanol.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Progabide.]
[R06AA02, diphenhydramine, The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Butorphanol.]
[A07DA01, diphenoxylate, The therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Butorphanol.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Quazepam.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Butorphanol.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Butorphanol.]
[C01BA03, disopyramide, The risk or severity of adverse effects can be increased when Disopyramide is combined with Butorphanol.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Butorphanol is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Butorphanol.]
[C03XA01, tolvaptan, The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Butorphanol.]
[N06AA16, dothiepin, The risk or severity of adverse effects can be increased when Dosulepin is combined with Butorphanol.]
[N06AA12, doxepin, The risk or severity of adverse effects can be increased when Doxepin is combined with Butorphanol.]
[A06AB06, sennosides, USP, The therapeutic efficacy of Sennosides can be decreased when used in combination with Butorphanol.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[N06AB06, sertraline, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Butorphanol is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[A08AA10, sibutramine, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Sibutramine.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Butorphanol.]
[A12CA02, sodium sulfate, The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Butorphanol.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Butorphanol is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Butorphanol is combined with Sumatriptan.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Butorphanol is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Thiopropazate.]
[G04BD01, emepronium, The risk or severity of adverse effects can be increased when Emepronium is combined with Butorphanol.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tianeptine.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Toloxatone.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Butorphanol.]
[C03CA04, torsemide, The therapeutic efficacy of Torasemide can be decreased when used in combination with Butorphanol.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Butorphanol is combined with Triclofos.]
[A03AB08, tridihexethyl, The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Butorphanol.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Trimethobenzamide.]
[N04AA12, tropatepine, The risk or severity of adverse effects can be increased when Tropatepine is combined with Butorphanol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Butorphanol.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Butorphanol is combined with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Butorphanol is combined with Veralipride.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Epinastine.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Venlafaxine.]
[N05CF02, zolpidem, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Zonisamide.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of hypotension and CNS depression can be increased when Moricizine is combined with Butorphanol.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ergotamine.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Estazolam.]
[C01CA15, gepefrine, Gepefrine may increase the analgesic activities of Butorphanol.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Butorphanol.]
[N04AA05, profenamine, The risk or severity of adverse effects can be increased when Profenamine is combined with Butorphanol.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Butorphanol.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ethotoin.]
[S01XA06, ethylmorphine, The therapeutic efficacy of Ethylmorphine can be decreased when used in combination with Butorphanol.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Butorphanol.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Butorphanol is combined with Sertindole.]
[R06AX12, terfenadine, The risk or severity of adverse effects can be increased when Terfenadine is combined with Butorphanol.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Butorphanol is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Fluvoxamine.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Fenfluramine.]
[R03CC04, fenoterol, The risk or severity of adverse effects can be increased when Fenoterol is combined with Butorphanol.]
[N02AB03, fentanyl, The therapeutic efficacy of Fentanyl can be decreased when used in combination with Butorphanol.]
[G04BD02, flavoxate, The risk or severity of adverse effects can be increased when Flavoxate is combined with Butorphanol.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Butorphanol is combined with Melitracen.]
[V03AZ01, ethanol, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Fluoxetine.]
[N05AF01, flupenthixol, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of hypotension and CNS depression can be increased when Fluphenazine is combined with Butorphanol.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Flurazepam.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Butorphanol is combined with Fluspirilene.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Alcuronium is combined with Butorphanol.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Furazolidone.]
[C03CA01, furosemide, The therapeutic efficacy of Furosemide can be decreased when used in combination with Butorphanol.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Butorphanol is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Butorphanol is combined with Amisulpride.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Gallamine is combined with Butorphanol.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Butorphanol is combined with Bifemelane.]
[N04BC06, cabergoline, The risk or severity of adverse effects can be increased when Cabergoline is combined with Butorphanol.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Methsuximide.]
[N01AH02, alfentanil, The therapeutic efficacy of Alfentanil can be decreased when used in combination with Butorphanol.]
[A06AH02, alvimopan, The risk or severity of adverse effects can be increased when Butorphanol is combined with Alvimopan.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Glutethimide.]
[A06AX01, glycerin, The therapeutic efficacy of Glycerin can be decreased when used in combination with Butorphanol.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Butorphanol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Butorphanol is combined with Halothane.]
[N05AH04, quetiapine, The risk or severity of adverse effects can be increased when Quetiapine is combined with Butorphanol.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Butorphanol is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Butorphanol is combined with Allobarbital.]
[B05CB03, magnesium citrate, The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Butorphanol.]
[A12CD02, sodium monofluorophosphate, The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Butorphanol.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Butorphanol.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Butorphanol.]
[R05DA03, hydrocodone, The therapeutic efficacy of Hydrocodone can be decreased when used in combination with Butorphanol.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Butorphanol.]
[A12BA02, potassium citrate, The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Butorphanol.]
[G04BD06, propiverine, The risk or severity of adverse effects can be increased when Propiverine is combined with Butorphanol.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Butorphanol is combined with Prothipendyl.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[A06AD21, sodium tartrate, The therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Butorphanol.]
[N01AH03, sufentanil, The therapeutic efficacy of Sufentanil can be decreased when used in combination with Butorphanol.]
[N06AA02, imipramine, The risk or severity of adverse effects can be increased when Imipramine is combined with Butorphanol.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Tizanidine.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be decreased when used in combination with Butorphanol.]
[N06AX17, milnacipran, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Milnacipran.]
[A03AA30, piperidolate, The risk or severity of adverse effects can be increased when Piperidolate is combined with Butorphanol.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Alprazolam.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ramelteon.]
[R06AE01, buclizine, The risk or severity of adverse effects can be increased when Buclizine is combined with Butorphanol.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Alprenolol.]
[C03BA02, quinethazone, The therapeutic efficacy of Quinethazone can be decreased when used in combination with Butorphanol.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Butorphanol is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Butorphanol is combined with Iproniazid.]
[N05AA07, chlorproethazine, The risk or severity of hypotension and CNS depression can be increased when Chlorproethazine is combined with Butorphanol.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Butorphanol is combined with Isocarboxazid.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Butorphanol.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Butorphanol.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Butorphanol.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ketanserin.]
[N05AH03, olanzapine, The risk or severity of adverse effects can be increased when Olanzapine is combined with Butorphanol.]
[N04BC09, rotigotine, Butorphanol may increase the sedative activities of Rotigotine.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Butorphanol.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Butorphanol.]
[A06AX03, lubiprostone, The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Butorphanol.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Lacosamide.]
[C03CC01, ethacrynic acid, The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Butorphanol.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Butorphanol is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Butorphanol.]
[C03DB01, amiloride, The therapeutic efficacy of Amiloride can be decreased when used in combination with Butorphanol.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Lisuride is combined with Butorphanol.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Lofepramine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Lorazepam.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Butorphanol.]
[G04BX01, magnesium hydroxide, The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Butorphanol.]
[A12CC10, magnesium oxide, The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Butorphanol.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Butorphanol can be increased when used in combination with Magnesium sulfate.]
[V04CX04, mannitol, The therapeutic efficacy of Mannitol can be decreased when used in combination with Butorphanol.]
[N06AA21, maprotiline, The risk or severity of adverse effects can be increased when Maprotiline is combined with Butorphanol.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Butorphanol.]
[C02BB01, mecamylamine, The risk or severity of adverse effects can be increased when Mecamylamine is combined with Butorphanol.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Butorphanol.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Medazepam.]
[A06AB07, cascara sagrada, The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Butorphanol.]
[C03BA05, mefruside, The therapeutic efficacy of Mefruside can be decreased when used in combination with Butorphanol.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Melatonin.]
[N02AB02, meperidine, The therapeutic efficacy of Meperidine can be decreased when used in combination with Butorphanol.]
[C01CA11, mephentermine, Mephentermine may increase the analgesic activities of Butorphanol.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Butorphanol.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Butorphanol.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Butorphanol.]
[N02AX05, meptazinol, The therapeutic efficacy of Meptazinol can be decreased when used in combination with Butorphanol.]
[C03BC01, mersalyl, The therapeutic efficacy of Mersalyl can be decreased when used in combination with Butorphanol.]
[N05AC03, mesoridazine, The risk or severity of hypotension and CNS depression can be increased when Mesoridazine is combined with Butorphanol.]
[N05AX13, paliperidone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Butorphanol is combined with Dolasetron.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Butorphanol.]
[N06BA03, methamphetamine, Metamfetamine may increase the analgesic activities of Butorphanol.]
[A03AB07, methantheline, The risk or severity of adverse effects can be increased when Methantheline is combined with Butorphanol.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Butorphanol is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Butorphanol.]
[S01EC05, methazolamide, The therapeutic efficacy of Methazolamide can be decreased when used in combination with Butorphanol.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Butorphanol is combined with Metergoline.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Butorphanol.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Butorphanol.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Butorphanol is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Butorphanol.]
[A06AC06, methylcellulose, The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Butorphanol.]
[V04CG05, methylene blue, Butorphanol may increase the serotonergic activities of Methylene blue.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Butorphanol.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Butorphanol is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Butorphanol.]
[A03FA01, metoclopramide, The therapeutic efficacy of Metoclopramide can be decreased when used in combination with Butorphanol.]
[C03BA08, metolazone, The therapeutic efficacy of Metolazone can be decreased when used in combination with Butorphanol.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Mianserin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Midazolam.]
[A06AA01, mineral oil, The therapeutic efficacy of Mineral oil can be decreased when used in combination with Butorphanol.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may increase the analgesic activities of Butorphanol.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Molindone.]
[N06AA09, amitriptyline, The risk or severity of adverse effects can be increased when Amitriptyline is combined with Butorphanol.]
[N02AA01, morphine, The therapeutic efficacy of Morphine can be decreased when used in combination with Butorphanol.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Butorphanol.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Butorphanol.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Butorphanol.]
[R03BB01, ipratropium bromide, The risk or severity of adverse effects can be increased when Ipratropium is combined with Butorphanol.]
[N06AA17, amoxapine, The risk or severity of adverse effects can be increased when Amoxapine is combined with Butorphanol.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Butorphanol is combined with Fosphenytoin.]
[N04BC04, ropinirole, Butorphanol may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Butorphanol is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The therapeutic efficacy of Nalbuphine can be decreased when used in combination with Butorphanol.]
[V03AB15, naloxone, The therapeutic efficacy of Butorphanol can be decreased when used in combination with Naloxone.]
[N07BB04, naltrexone, The therapeutic efficacy of Naltrexone can be decreased when used in combination with Butorphanol.]
[S01GA01, naphazoline, Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[N06BA01, amphetamine, Amphetamine may increase the analgesic activities of Butorphanol.]
[N06AX21, duloxetine, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Butorphanol.]
[N01AH06, remifentanil, The therapeutic efficacy of Remifentanil can be decreased when used in combination with Butorphanol.]
[N05AX14, iloperidone, The risk or severity of adverse effects can be increased when Butorphanol is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Nialamide.]
[C08CA04, nicardipine, The risk or severity of adverse effects can be increased when Nicardipine is combined with Butorphanol.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Nitrazepam.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Butorphanol is combined with Zaleplon.]
[N04BC05, pramipexole, Butorphanol may increase the sedative activities of Pramipexole.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Nomifensine.]
[N06AA10, nortriptyline, The risk or severity of adverse effects can be increased when Nortriptyline is combined with Butorphanol.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Opipramol.]
[N02AA02, opium, The therapeutic efficacy of Opium can be decreased when used in combination with Butorphanol.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Oxazepam.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Oxprenolol.]
[N02AA05, oxycodone, The therapeutic efficacy of Oxycodone can be decreased when used in combination with Butorphanol.]
[N02AA11, oxymorphone, The therapeutic efficacy of Oxymorphone can be decreased when used in combination with Butorphanol.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Oxypertine.]
[A03AB03, oxyphenonium, The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Butorphanol.]
[N05AH05, asenapine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.]
[M03AC01, pancuronium, The risk or severity of adverse effects can be increased when Pancuronium is combined with Butorphanol.]
[N05CC05, paraldehyde, Butorphanol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pargyline.]
[G04BD11, fesoterodine, The risk or severity of adverse effects can be increased when Fesoterodine is combined with Butorphanol.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Penfluridol.]
[N02AD01, pentazocine, The therapeutic efficacy of Pentazocine can be decreased when used in combination with Butorphanol.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Butorphanol.]
[N05AB10, perazine, The risk or severity of hypotension and CNS depression can be increased when Perazine is combined with Butorphanol.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pergolide.]
[N05AB03, perphenazine, The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Butorphanol.]
[N02AD02, phenazocine, The therapeutic efficacy of Phenazocine can be decreased when used in combination with Butorphanol.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Phenelzine.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Phenobarbital is combined with Butorphanol.]
[A06AB01, oxyphenisatin, The therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Butorphanol.]
[N01AH04, phenoperidine, The therapeutic efficacy of Phenoperidine can be decreased when used in combination with Butorphanol.]
[A08AA01, phentermine, Phentermine may increase the analgesic activities of Butorphanol.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Butorphanol.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pindolol.]
[N05AC04, pipothiazine, The risk or severity of hypotension and CNS depression can be increased when Pipotiazine is combined with Butorphanol.]
[A02BX03, pirenzepine, The risk or severity of adverse effects can be increased when Pirenzepine is combined with Butorphanol.]
[N02AC03, pirinitramide, The therapeutic efficacy of Piritramide can be decreased when used in combination with Butorphanol.]
[N02CX01, pizotyline, The risk or severity of adverse effects can be increased when Pizotifen is combined with Butorphanol.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Butorphanol is combined with Proxibarbal.]
[A06AD15, polyethylene glycols, The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Butorphanol.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Butorphanol is combined with Alosetron.]
[C03AA05, polythiazide, The therapeutic efficacy of Polythiazide can be decreased when used in combination with Butorphanol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Butorphanol is combined with Prazepam.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Prilocaine.]
[N03AA03, primidone, The risk or severity of adverse effects can be increased when Primidone is combined with Butorphanol.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Procarbazine.]
[N05AB04, prochlorperazine, The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Butorphanol.]
[N04AA04, procyclidine, The risk or severity of adverse effects can be increased when Procyclidine is combined with Butorphanol.]
[N05AA03, promazine, The risk or severity of adverse effects can be increased when Promazine is combined with Butorphanol.]
[R06AD02, promethazine, The risk or severity of adverse effects can be increased when Promethazine is combined with Butorphanol.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Butorphanol is combined with Propanidid.]
[A03AB05, propantheline, The risk or severity of adverse effects can be increased when Propantheline is combined with Butorphanol.]
[N05AC01, periciazine, The risk or severity of hypotension and CNS depression can be increased when Periciazine is combined with Butorphanol.]
[N05CM06, propiomazine, The risk or severity of adverse effects can be increased when Propiomazine is combined with Butorphanol.]
[N01AX10, propofol, Butorphanol may increase the sedative activities of Propofol.]
[N02AC04, propoxyphene, The therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Butorphanol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Butorphanol is combined with Rizatriptan.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Butorphanol.]
[R01BA02, pseudoephedrine, Pseudoephedrine may increase the analgesic activities of Butorphanol.]
[N05AX12, aripiprazole, The risk or severity of adverse effects can be increased when Aripiprazole is combined with Butorphanol.]
[A03AB15, diphemanil, The risk or severity of adverse effects can be increased when Diphemanil is combined with Butorphanol.]
[A03AB09, isopropamide, The risk or severity of adverse effects can be increased when Isopropamide is combined with Butorphanol.]
[S01FA03, methscopolamine, The risk or severity of adverse effects can be increased when Methscopolamine is combined with Butorphanol.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Butorphanol.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Butorphanol is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Butorphanol is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Butorphanol is combined with Mepyramine.]
[C01BA01, quinidine, The risk or severity of adverse effects can be increased when Quinidine is combined with Butorphanol.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Butorphanol.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Butorphanol.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Butorphanol is combined with Oxitriptan.]
[S01FA02, scopolamine, The risk or severity of adverse effects can be increased when Scopolamine is combined with Butorphanol.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Butorphanol.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Butorphanol is combined with Selegiline.]
[V04CC01, sorbitol, The therapeutic efficacy of Sorbitol can be decreased when used in combination with Butorphanol.]
[C03DA01, spironolactone, The therapeutic efficacy of Spironolactone can be decreased when used in combination with Butorphanol.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Butorphanol.]
